SecBot SecBot

NEPH

NEPHROS INC
Nasdaq· Surgical & Medical Instruments & Apparatus· Inc. DE· CIK 0001196298 Healthcare & Medical Devices
$3.61 +0.08 (+2.12%)
Oct 26 4:00 PM ET · prev $3.53
Market cap
$38.3M
Nano cap
Median target
$6.00
+66% · range $4.75–8.00
Next earnings
Nov 5
in 10 days · EPS est. $0.03
1 year
−33.5%
from $5.42 · Oct 27
30 days
−10.5%
from $4.03
52-week range
$2.78–5.79
−38% from high · low Apr 7
Avg volume 20D
43.3K
Oct 6 spike 179.8K
Short interest
25.3K
≈0.2% of shares · −45.5%
Days to cover
1.4
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
7
analyzed by SecBot
SecBot read MIXED 5 reports · 90 days
Balance 1 bearish · 1 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 5/5 ·Next Earnings date, Nov 5, 2026
Strongest NEUTRAL Nephros Inc. filed its definitive proxy statement for the 2026 Annual Meeting, seeking the election of CEO…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 3 added (0 new), 0 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate $0.025 → $0.030 over 90 days. 1 up, 1 down in 30 days.

  • Short sellersCOVERING

    Short interest −45.5% to 25.3K shares. 1.4 days to cover, ≈0.2% of shares.

  • TrendDOWNTREND

    10% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
CITADEL ADVISORS LLCADD29,044$103.7K
NORTHERN TRUST CORPADD16,706$59.6K
JONES FINANCIAL COMPANIES LLLPDOUBLED227$819.00
MORGAN STANLEYDOUBLED110,915$330.5K
DIMENSIONAL FUND ADVISORS LPADD20,745$61.8K
GOLDMAN SACHS GROUP INCTRIM14,163$42.2K
OSAIC HOLDINGS, INC.NEAR_EXIT175$521.00
RENAISSANCE TECHNOLOGIES LLCADD103,772$506.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Aug 2025
12-month targets · 3 analysts

Price is below the lowest target. Median implies +66%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Aug 8, 2025Maxim Group
MAINTAIN
MAINTAINBuy
Nov 12, 2024Benchmark
REITERATE
REITERATESpeculative Buy
May 15, 2024Benchmark
REITERATE
REITERATESpeculative Buy
Mar 8, 2024Benchmark
UPGRADE
UPGRADESpeculative Buy
Jan 26, 2021B. Riley Securities
INITIATE
INITIATEBuy
Oct 24, 2019Benchmark
INITIATE
INITIATESpeculative Buy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Sep 14, 2026
Amron Arthur H
Director
OTHER17,749 sh
Sep 14, 2026
Amron Arthur H
Director
OTHER$89.7K
Sep 14, 2026
Amron Arthur H
Director
OTHER2,836 sh
Sep 14, 2026
WEXFORD CAPITAL LP
10%+ Owner
OTHER$89.7K
Sep 14, 2026
WEXFORD CAPITAL LP
10%+ Owner
OTHER3,355,111 sh
Aug 18, 2026
WEXFORD CAPITAL LP
10%+ Owner
EXERCISE$2.9K
Aug 18, 2026
WEXFORD CAPITAL LP
10%+ Owner
EXERCISE3,765 sh
Aug 12, 2026
Amron Arthur H
Director
AWARD2,418 sh

Earnings setup

Estimates
Nov 5
reports in 10 days
$0.03
EPS estimate, this quarter
+20%
estimate change, 90 days
1↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$0.03$0.03–$0.03+50.0%$5.5M
Next Q$0.03$0.03–$0.03+200.0%$5.4M
Current FY$0.17$0.17–$0.17+325.0%$22.1M
Next FY$0.21$0.21–$0.21+110.0%$25.7M

Short side

FINRA· Sep 30, 2026
25,302
shares short
-45.5%
vs prior settlement
1.4
days to cover
≈0.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 14, 2026 SEC
Nephros Inc. filed its definitive proxy statement for the 2026 Annual Meeting, seeking the election of CEO Robert…
DEF 14A — Impact 5/10
Oct 13, 2026 SEC
Nephros filed an 8-K announcing its 2026 Annual Meeting of Stockholders will be held virtually on November 25, 2026…
8-K — Impact 2/10
Sep 16, 2026 SEC
Wexford Capital LP filed Amendment No. 12 to its Schedule 13D on Nephros, reporting that it ceased to be the…
SC 13D/A — Impact 6/10
Sep 14, 2026 Insider
Amron Arthur H acquired 17,749 shares
Director
Sep 14, 2026 Insider
Amron Arthur H acquired 22,710 shares
Director @ $3.95 ($89.7K)
Sep 14, 2026 Insider
Amron Arthur H acquired 2,836 shares
Director
Aug 5, 2026 Earnings calendar
NEPH Q2 2026 Earnings Scheduled — 2026-08-05
Jun 30, 2026 Inst.
CITADEL ADVISORS LLC — ADD
29,044 shares ($103.7K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
NEPH Q3 2026 Earnings Scheduled — 2026-11-05
Recent
Aug 5, 2026
Earnings date
NEPH Q2 2026 Earnings Scheduled — 2026-08-05
Jul 22, 2026
Earnings date
NEPH Q2 2026 Earnings Scheduled — 2026-07-22
Jul 20, 2026
Press release
Nephros to Participate in the “Health, Wellness & Longevity” Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22nd at 10:00 a.m. ET
Nephros to Participate in the “Health, Wellness & Longevity” Virtual Conference Presented by Maxim Group LLC on Wednesday, July 22nd at 10:00 a.m. ET
Jun 18, 2026
Press release
Nephros to Host Virtual Investor Event: “Beyond Filtration: The Nephros Model in Action”
Nephros to Host Virtual Investor Event: “Beyond Filtration: The Nephros Model in Action”
Jun 16, 2026
Press release
Nephros Positions Ultrafiltration Technology as a Solution to Emerging Microplastic Risk in Water
Nephros Positions Ultrafiltration Technology as a Solution to Emerging Microplastic Risk in Water

SecBot reports

7 filings · 2 press releases · 1 bullish · 1 bearish · 1 mixed · 4 neutral
All NEPH filing & press-release reports (9)